Therapeutic Peptide Development Services for Cardiovascular Diseases

Numerous studies have reported that vasoactive peptides have the potential to be developed as novel therapeutic agents for cardiovascular diseases. With the goal of advancing research for the discovery of new cardiovascular drugs, Ace Therapeutics strives to help clients conduct research and development of therapeutic peptides for cardiovascular diseases.

Therapeutic Peptides for Cardiovascular Diseases

Since the introduction of therapeutic insulin, peptides have played an important role in medical practice. To date, more than a hundred peptide drugs have been approved worldwide, and are widely used in the therapy of cardiovascular diseases.

• Natriuretic Peptides
  Natriuretic peptides activated during heart failure have important cardioprotective effects. Atrial natriuretic peptide and brain natriuretic peptide act as antagonists of angiotensin II through diuretic effects, vasodilatory effects, and inhibition of aldosterone secretion.
• Adrenomedullin
  Adrenomedullin (AM) is a member of the calcitonin peptide family. Several experimental studies have been conducted to show that AM is beneficial in heart failure, acute myocardial infarction, and pulmonary hypertension.
• Bradykinin
  Bradykinin, a peptide containing nine amino acids, is a potent endothelium-dependent vasodilator that contributes to vasodilation in the systemic circulation and lowers blood pressure.

Fig. 1 Relationship of circulating leptin levels and cardiovascular dysfunction. (Zhao S, et al., 2021)

Ace Therapeutics is committed to providing therapeutic peptide development services to speed up the development of therapeutic peptides for cardiovascular diseases.

Identification and Validation of Peptide Therapeutic Targets

We can use genomics, proteomics and transcriptomics technologies to identify key genes or proteins associated with cardiovascular disease as potential targets, and verify the role and importance of the targets in cardiovascular disease through in vitro and in vivo experiments.

Discovery of Therapeutic Peptides for Cardiovascular Diseases

• Natural Peptides
  We can identify candidate peptides for the treatment of cardiovascular diseases from natural sources such as animal venoms, plant extracts or endogenous peptides.
• Synthetic Peptides
  In addition, we can use bioinformatics computational methods to design peptides based on known protein-protein interactions or active sites of larger proteins.
• Cardiovascular-derived Therapeutic Peptidomimetics
  Some cardiovascular-derived peptides, such as angiotensin II, endothelin, and bradykinin, are important regulators of the cardiovascular system, and they are closely related to the pathogenesis of cardiovascular diseases. We can develop peptide derivatives or mimetics based on these cardiovascular peptides as potential therapeutics for the treatment of cardiovascular diseases.

Peptide Lead Optimization

Therapeutic peptides for the treatment of cardiovascular diseases usually need to exert their efficacy in the blood circulation, which has high requirements on the stability and biofilm permeability. We can modify the peptide candidates to improve their stability and half-life so as to make them have ideal pharmacokinetic characteristics.

Efficacy Evaluation of Therapeutic Peptides

We can test the potency and safety of peptides in cardiovascular-related cellular models or animal models to assess their regulatory effects on targets.

Drug Delivery System Development of Therapeutic Peptides

We can develop appropriate delivery systems for therapeutic peptides of cardiovascular diseases, such as lipid nanoparticles (LNPs), polymer nanoparticles, microspheres, and nano cellular micelles, in order to improve peptide stability and targeted delivery efficiency.

Preclinical Evaluation of Therapeutic Peptides

We can provide preclinical pharmacokinetic (PK), pharmacodynamic (PD) and toxicology studies for therapeutic peptides in cardiovascular diseases.

Ace Therapeutics is a CRO company dedicated to providing outsourcing services for cardiovascular drug development. We can provide R&D services covering the full preclinical cycle of new drug discovery and development according to our clients' customized needs. If you are interested in our services, please don't hesitate to contact us.

1. Zhao, S.; et al. Adiponectin, leptin and cardiovascular disorders. Circ Res. 2021, 128(1):136-149.